How to Trip Rapid Review

Step 1: Select articles relevant to your search (remember the system is only optimised for single intervention studies)

Step 2: press

Step 3: review the result, and maybe amend the or if you know better! If we're unsure of the overall sentiment of the trial we will display the conclusion under the article title. We then require you to tell us what the correct sentiment is.

1,491 results for

First Generation Sulfonylurea

by
...
Latest & greatest
Alerts

Export results

Use check boxes to select individual results below

SmartSearch available

Trip's SmartSearch engine has discovered connected searches & results. Click to show

161. Diagnosis and management of glycogen storage disease type I: a practice guideline of the American College of Medical Genetics and Genomics

Diagnosis and management of glycogen storage disease type I: a practice guideline of the American College of Medical Genetics and Genomics 1 © American College of Medical Genetics and Genomics ACMG St And ArdS And GuidelineS PURPOSE This guideline is intended as an educational resource. It high- lights current practices and therapeutic approaches to the diagnosis and management of GSD I and its early and long- term complications. GENERAL BACKGROUND History In 1929, von Gierke described glycogen (...) and discovered that the absence of the enzyme glucose-6-phos- phatase (G6Pase) caused von Gierke disease, establishing the first metabolic disorder in which an enzyme defect was identi- fied. Two patients had almost total deficiency of hepatic G6Pase; the remaining four patients had normal enzyme activity. Early on, the authors recognized the variability of the hepatic GSDs. In 1978, Narisawa et al. 3 explained the paradox of the four patients with GSD and normal enzyme activity when he described GSD type Ib

2014 American College of Medical Genetics and Genomics

162. Tenelia (teneligliptin hydrobromide hydrate)

Tenelia (teneligliptin hydrobromide hydrate) Report on the Deliberation Results April 27, 2012 Evaluation and Licensing Division, Pharmaceutical and Food Safety Bureau, Ministry of Health, Labour and Welfare [Brand name] Tenelia Tablets 20 mg [Non-proprietary name] Teneligliptin Hydrobromide Hydrate (JAN*) [Applicant] Mitsubishi Tanabe Pharma Corporation [Date of application] August 26, 2011 [Results of deliberation] In the meeting held on April 27, 2012, the First Committee on New Drugs (...) ] Type 2 diabetes mellitus; The drug product should be used only in patients who have not sufficiently responded to either of the following treatments. (a) Diet and/or exercise therapy alone (b) Use of sulfonylureas in addition to diet and/or exercise therapy (c) Use of thiazolidinediones in addition to diet and/or exercise therapy [Dosage and administration] The usual adult dosage is 20 mg of teneligliptin administered orally once daily. If efficacy is insufficient, the dose may be increased up

2012 Pharmaceuticals and Medical Devices Agency, Japan

163. Heart Disease and Stroke Statistics?2016 Update

% higher odds with sibling history), stroke (50% higher odds with history in a first-degree relative), atrial fibrillation (AF; 80% higher odds with parental history), heart failure (70% higher odds with parental history), and peripheral arterial disease (80% higher odds with family history). This excess risk reflects genetic, epigenetic, and shared behavioral and environmental risk factors. High Blood Cholesterol and Other Lipids (Chapter 8) 75.7% of children and 46.6% of adults have ideal cholesterol (...) in men. In addition, there has been variation in the trends over time for each individual component of the metabolic syndrome. Generally, the national prevalences of hypertriglyceridemia and elevated blood pressure have decreased, whereas hyperglycemia and elevated waist circumference have increased. However, these trends also vary significantly by sex and race/ethnicity. Perhaps most importantly with respect to meeting the 2020 goals, the prevalence of metabolic syndrome increases with greater

2014 American Heart Association

164. Randomized, Double-blind (db), Placebo-controlled 18 Week Study of Linagliptin (BI 1356) in Type 2 Diabetic Patients With Insufficient Glycaemic Control on a Sulfonylurea Drug

Randomized, Double-blind (db), Placebo-controlled 18 Week Study of Linagliptin (BI 1356) in Type 2 Diabetic Patients With Insufficient Glycaemic Control on a Sulfonylurea Drug Randomized, Double-blind (db), Placebo-controlled 18 Week Study of Linagliptin (BI 1356) in Type 2 Diabetic Patients With Insufficient Glycaemic Control on a Sulfonylurea Drug - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information (...) . Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved studies (100). Please remove one or more studies before adding more. Randomized, Double-blind (db), Placebo-controlled 18 Week Study of Linagliptin (BI 1356) in Type 2 Diabetic Patients With Insufficient Glycaemic Control on a Sulfonylurea Drug The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does

2009 Clinical Trials

165. Efficacy and Safety Study of MP-513 in Combination With Sulfonylurea in Patients With Type 2 Diabetes

remove one or more studies before adding more. Efficacy and Safety Study of MP-513 in Combination With Sulfonylurea in Patients With Type 2 Diabetes The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our for details. ClinicalTrials.gov Identifier: NCT00974090 Recruitment Status : Completed First Posted : September 10, 2009 Results First Posted : May 8 (...) Efficacy and Safety Study of MP-513 in Combination With Sulfonylurea in Patients With Type 2 Diabetes Efficacy and Safety Study of MP-513 in Combination With Sulfonylurea in Patients With Type 2 Diabetes - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved studies (100). Please

2009 Clinical Trials

166. CANagliflozin Treatment And Trial Analysis-Sulfonylurea (CANTATA-SU) SGLT2 Add-on to Metformin Versus Glimepiride

studies (100). Please remove one or more studies before adding more. CANagliflozin Treatment And Trial Analysis-Sulfonylurea (CANTATA-SU) SGLT2 Add-on to Metformin Versus Glimepiride The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our for details. ClinicalTrials.gov Identifier: NCT00968812 Recruitment Status : Completed First Posted : August 31, 2009 (...) CANagliflozin Treatment And Trial Analysis-Sulfonylurea (CANTATA-SU) SGLT2 Add-on to Metformin Versus Glimepiride CANagliflozin Treatment And Trial Analysis-Sulfonylurea (CANTATA-SU) SGLT2 Add-on to Metformin Versus Glimepiride - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved

2009 Clinical Trials

167. Safety and Tolerability of AZD1656 in Type 2 Diabetes Mellitus (T2DM) Patients Treated With Metformin and Sulfonylurea

number of saved studies (100). Please remove one or more studies before adding more. Safety and Tolerability of AZD1656 in Type 2 Diabetes Mellitus (T2DM) Patients Treated With Metformin and Sulfonylurea The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our for details. ClinicalTrials.gov Identifier: NCT00995787 Recruitment Status : Completed First (...) Principal Investigator: Marcus Dr. Marcus Hompesch, Dr Profil Institute for Clinical Research Inc.855 3rd Avenue, Suite 4400Chula VistaCA 91911, USA More Information Go to Layout table for additonal information Responsible Party: MSD, AstraZeneca ClinicalTrials.gov Identifier: Other Study ID Numbers: D1020C00026 First Posted: October 15, 2009 Last Update Posted: February 26, 2010 Last Verified: February 2010 Keywords provided by AstraZeneca: Type II diabetes mellitus metformin sulfonylurea Additional

2009 Clinical Trials

168. GLP-1 Receptor Agonist Lixisenatide in Patients With Type 2 Diabetes for Glycemic Control and Safety Evaluation, on Top of Basal Insulin +/- Sulfonylurea (GETGOAL-L-ASIA)

Party: Sanofi ClinicalTrials.gov Identifier: Other Study ID Numbers: EFC10887 First Posted: March 20, 2009 Results First Posted: October 11, 2016 Last Update Posted: October 11, 2016 Last Verified: August 2016 Keywords provided by Sanofi: hyperglycemia GLP-1 sulfonylurea insulin Additional relevant MeSH terms: Layout table for MeSH terms Diabetes Mellitus Diabetes Mellitus, Type 2 Glucose Metabolism Disorders Metabolic Diseases Endocrine System Diseases Insulin Insulin, Globin Zinc Lixisenatide (...) GLP-1 Receptor Agonist Lixisenatide in Patients With Type 2 Diabetes for Glycemic Control and Safety Evaluation, on Top of Basal Insulin +/- Sulfonylurea (GETGOAL-L-ASIA) GLP-1 Receptor Agonist Lixisenatide in Patients With Type 2 Diabetes for Glycemic Control and Safety Evaluation, on Top of Basal Insulin +/- Sulfonylurea (GETGOAL-L-ASIA) - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search

2009 Clinical Trials

169. Evaluation of a Mixed Meal Test for Diagnosis and Characterization and Type 3c Diabetes Mellitus Secondary to Pancreatic Cancer and Chronic Pancreatitis (DETECT)

. Federal Government. of clinical studies and talk to your health care provider before participating. Read our for details. ClinicalTrials.gov Identifier: NCT03460769 Recruitment Status : Recruiting First Posted : March 9, 2018 Last Update Posted : October 5, 2018 See Sponsor: M.D. Anderson Cancer Center Collaborator: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) Information provided by (Responsible Party): M.D. Anderson Cancer Center Study Details Study Description Go (...) Criteria Go to Information from the National Library of Medicine Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Layout table for eligibility information Ages Eligible for Study: 40 Years to 84 Years (Adult, Older Adult) Sexes Eligible for Study: All

2018 Clinical Trials

170. A Comparative Study of the Effects of QS-M Needle Free Injector and Glargine Pen Subcutaneous Injection of Insulin Glargine on Insulin Use

Identifier: NCT03420040 Recruitment Status : Enrolling by invitation First Posted : February 2, 2018 Last Update Posted : February 2, 2018 Sponsor: Xijing Hospital Information provided by (Responsible Party): Xijing Hospital Study Details Study Description Go to Brief Summary: A clinical study of the use of glargine insulin in 2 subjects with type two diabetes in China was carried out. The two kinds of injection methods were evaluated as subcutaneous injection of insulin glargine. Condition or disease (...) glucose between baseline to week 4 [ Time Frame: baseline and week 4 ] fasting blood glucose are measured at baseline and week 4 Eligibility Criteria Go to Information from the National Library of Medicine Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information

2018 Clinical Trials

171. Comparing Efficacy and Safety of CinnaGen-liraglutide Versus Victoza® in Patients With Type II Diabetes

and Interventions Go to Arm Intervention/treatment Experimental: CinnaGen-liraglutide CinnaGen-liraglutide (Liraglutide 6 MG/ML Pen Injector by CinnaGen Company) will be administered 1.8 mg/day subcutaneously. Doses of CinnaGen-liraglutide will be up-titrated from 0.6 mg/day in the first week to 1.2 mg/day in the second, third and fourth weeks, up to 1.8 mg/day from the start of the fifth week to the end of 26th week. Patients in this group will continue to receive metformin along with a Sulfonylurea/non (...) Patients who were receiving Sulfonylurea/non-sulfonylurea insulin secretagogues with maximum tolerable dose prior to study will continue to receive it during the study. Other Name: Sulfonylurea or non-sulfonylurea insulin secretagogues Active Comparator: Victoza® Victoza® (Liraglutide 6 MG/ML Pen Injector by Novo Nordisk Company) will be administered 1.8 mg/day subcutaneously. Doses of Victoza® will be up-titrated from 0.6 mg/day in the first week to 1.2 mg/day in the second, third and fourth weeks, up

2018 Clinical Trials

172. Lanifibranor in Patients With Type 2 Diabetes & Nonalcoholic Fatty Liver Disease

medications, the dose of these medications will be kept stable throughout the study and baseline studies performed as outlined below. If the HbA1c is > 8.0% but ≤ 9.5%, metformin (minimum dose required: 1,000 mg/day for metformin) and/or a sulfonylurea (minimum dose required: glimepiride 2 mg once daily) will be added, or doses maximized, during the first 2 weeks of the lead-in period. Afterwards, patient's metformin or sulfonylurea dose will be maintained at the new dose stable for 4 weeks before (...) more. Lanifibranor in Patients With Type 2 Diabetes & Nonalcoholic Fatty Liver Disease The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. of clinical studies and talk to your health care provider before participating. Read our for details. ClinicalTrials.gov Identifier: NCT03459079 Recruitment Status : Recruiting First Posted : March 8, 2018 Last Update

2018 Clinical Trials

173. Hypoglycemia and Autonomic Nervous System Function- B2

contact the study research staff using the contacts provided below. For general information, Layout table for eligibility information Ages Eligible for Study: 18 Years to 55 Years (Adult) Sexes Eligible for Study: All Accepts Healthy Volunteers: No Criteria Inclusion Criteria: Males and females age 18 to 55 years Type 2 Diabetes Mellitus controlled by diet, exercise and non-insulin glycemic control agents (metformin, thiazolidinediones, sulfonylureas, dipeptidyl peptidase-4 inhibitors, sodium-glucose (...) Function- B2 (HypoANS-B2) The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. of clinical studies and talk to your health care provider before participating. Read our for details. ClinicalTrials.gov Identifier: NCT03422471 Recruitment Status : Recruiting First Posted : February 5, 2018 Last Update Posted : February 5, 2018 See Sponsor: Brigham and Women's

2018 Clinical Trials

174. Once-Weekly Oral Aminopterin for the Treatment of Subjects With Moderate-To-Severe Psoriasis

studies before adding more. Once-Weekly Oral Aminopterin for the Treatment of Subjects With Moderate-To-Severe Psoriasis The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. of clinical studies and talk to your health care provider before participating. Read our for details. ClinicalTrials.gov Identifier: NCT03431974 Recruitment Status : Recruiting First Posted (...) to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Layout table for eligibility information Ages Eligible for Study: 18 Years and older (Adult, Older Adult) Sexes Eligible for Study: All Accepts Healthy Volunteers: No Criteria Inclusion Criteria: Be 18 years of age or older. Have a diagnosis of moderate-to-severe psoriasis for at least 6 months confirmed by a dermatologist, defined here

2018 Clinical Trials

175. Multifactorial Intervention on Diabetes (MIDiab Study)

Study) The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. of clinical studies and talk to your health care provider before participating. Read our for details. ClinicalTrials.gov Identifier: NCT03430284 Recruitment Status : Recruiting First Posted : February 12, 2018 Last Update Posted : September 5, 2018 See Sponsor: Shandong Provincial Hospital Information (...) guidelines recommend an integrated multifactorial treatment approach. In this study, we aim to evaluate the effect on diabetic vascular complications of a multifactorial intervention comprising behavior modification, polypharmacological therapy and periodical monitoring in patients with type 2 diabetes. Condition or disease Intervention/treatment Phase Diabetes Mellitus, Type 2 Behavioral: Lifestyle therapy Drug: Pharmacotherapy Other: Monitoring and management Other: General treatment Phase 4 Study

2018 Clinical Trials

176. CloudConnect: Predictive And Retrospective Clinical Decision Support For Chronic Disease Management

: Recruiting First Posted : September 18, 2018 Last Update Posted : January 11, 2019 See Sponsor: University of Virginia Collaborator: National Library of Medicine (NLM) Information provided by (Responsible Party): Daniel Chernavvsky, MD, CRC, University of Virginia Study Details Study Description Go to Brief Summary: This study is to assess an approach of self-management called CloudConnect, evaluating the impact of CloudConnect Reports on patient engagement, adolescent/parent discussion, and clinical (...) - and post-study Family Communication Inventory questionnaire and the weekly communication assessments. Eligibility Criteria Go to Information from the National Library of Medicine Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Layout table

2018 Clinical Trials

177. Personalized Glucose Optimization Through Nutritional Intervention

Optimization Through Nutritional Intervention (PERSON) The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. of clinical studies and talk to your health care provider before participating. Read our for details. ClinicalTrials.gov Identifier: NCT03708419 Recruitment Status : Recruiting First Posted : October 17, 2018 Last Update Posted : October 17, 2018 See Sponsor (...) of first phase insulin secretion and insulin sensitivity during a 2-hour 7-points oral glucose tolerance test (OGTT). Disposition index will be calculated as follows: [Insulin sensitivity index (ISI) * (AUC30 min insulin / AUC30 min glucose)], where AUC30 min is the area under the curve between 0 and 30 minutes of the OGTT for insulin (pmol/l) and glucose (mmol/l), respectively, and ISI is defined as: [10,000 ÷ square root of (fasting plasma glucose (mmol/l) x fasting insulin (pmol/l)) x (mean glucose

2018 Clinical Trials

178. Glibenclamide Advantage in Treating Edema After Intracerebral Hemorrhage

. Glibenclamide Advantage in Treating Edema After Intracerebral Hemorrhage (GATE-ICH) The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our for details. ClinicalTrials.gov Identifier: NCT03741530 Recruitment Status : Enrolling by invitation First Posted : November 15, 2018 Last Update Posted : December 3, 2018 Sponsor: Xijing Hospital Information provided (...) ] Eligibility Criteria Go to Information from the National Library of Medicine Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Layout table for eligibility information Ages Eligible for Study: 18 Years and older (Adult, Older Adult) Sexes Eligible for Study

2018 Clinical Trials

179. IDegLira HIGH Trial

and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. of clinical studies and talk to your health care provider before participating. Read our for details. ClinicalTrials.gov Identifier: NCT03737240 Recruitment Status : Recruiting First Posted : November 9, 2018 Last Update Posted : January 25, 2019 See Sponsor: Emory University Collaborator: Novo Nordisk A/S Information provided by (Responsible Party): Rodolfo Galindo, Emory University Study Details Study (...) will be compared between study groups. Eligibility Criteria Go to Information from the National Library of Medicine Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Layout table for eligibility information Ages Eligible for Study: 18 Years to 80 Years (Adult

2018 Clinical Trials

180. Take a pill and stop aging. Really?

lifetime. Hence, rapamycin is being evaluated for its effect on lifespan, cardiac function and perhaps cancer onset and immune function. Drug companies have not put a lot of interest into anti-aging drugs for three possible reasons. First, the knowledge base upon which to develop such drugs has just not been available. Second, natural compounds, such as antioxidants and generic drugs like metformin, don’t offer much opportunity for profit. Third, it has been unclear if the FDA would approve (...) longer than normal. So it was interesting that a of a U.K. Registry of 180,000 people showed that individuals with diabetes mellitus who took metformin lived longer than those treated with another diabetes drug, a sulfonylurea. Of course, there may have been variations unappreciated in the two groups leading their doctors to prescribe one drug versus another. Still, the difference in lifespan was unexpected and intriguing. Further, the older diabetic patients on metformin also lived longer than older

2018 KevinMD blog

To help you find the content you need quickly, you can filter your results via the categories on the right-hand side >>>>